Product Description
Ophthalmic Solution for dry eye disease (DED) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03598699)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AxeroVision
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Keratoconjunctivitis Sicca|Dry Eye Syndromes|Dry Eye Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03598699 |
AXR201701 | P2 |
Completed |
Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca |
2018-12-28 |
49% |
2023-10-15 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|